A Case of Successful Treatment of Aplastic Anemia Induced by Immune Checkpoint Inhibitors for Lung Cancer

Chihiro Sumi; Masayo Yamamoto; Rena Sasaki; Takuya Funayama; Takeshi Saito; Mayumi Hatayama; Motohiro Shindo; Yasuhiro Umekage; Takaaki Sasaki; Sayaka Yuzawa; Mishie Tanino; Shuichiro Takahashi

doi:10.2169/internalmedicine.5590-25

Chihiro Sumi, Masayo Yamamoto, Rena Sasaki, Takuya Funayama, Takeshi Saito, Mayumi Hatayama, Motohiro Shindo, Yasuhiro Umekage, Takaaki Sasaki, Sayaka Yuzawa, Mishie Tanino, Shuichiro Takahashi

著者情報

キーワード: Immune checkpoint inhibitors, Immune-related adverse events, Aplastic anemia, Eltrombopag

ジャーナルオープンアクセス早期公開

論文ID: 5590-25

DOI https://doi.org/10.2169/internalmedicine.5590-25

詳細

抄録

Immune checkpoint inhibitors (ICIs) are effective against many types of cancers. However, these drugs can trigger unintended immune attacks on normal tissues, leading to a range of side effects known as immune-related adverse events (irAEs). Involvement of the hematopoietic system in irAEs is rare, and a standard treatment has not yet been established. We herein report a 72-year-old man with non-small-cell lung cancer who developed aplastic anemia (AA) after ICI treatment. Eltrombopag improved the long-term blood count without causing severe infection. This case suggests that eltrombopag may be a viable treatment option for ICI-induced AA.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）